Antiva Biosciences Company
Antiva Biosciences is a biopharmaceutical company developing therapeutics for the treatment of diseases caused by HPV infection. The company's medicinal chemistry platform focuses on the development and commercialization of direct-acting antivirals for infections with the human papillomavirus, herpes group viruses, HIV, and animal retroviruses, enabling patients to recover from HPV-related diseases and other viruses.
Investors
Founded Date:
01-01-2012
Total Funding:
$87,346,025
Investor Type:
N/A
Employee Number:
11-50
Investment Stage:
N/A
Funding Status:
Late Stage Venture
Number Of Exists:
N/A
Technology:
Cancer
Last Funding Type:
Series D
Investors Number:
18
Last Funding Date:
2021-11-02
Industry:
General Health Care
Headquarters:
Del Mar, California, United States
Estimated Revenue:
$1M to $10M